Share:
Original Article

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy

Author Affiliation(s)

Abstract

Introduction: Visceral adipose tissue (VAT) has a greater relationship with the genesis of the metabolic syndrome and the pathology associated with obesity.


Methods: A cross-sectional study of patients with moderate-severe psoriasis in the Psoriasis Unit of the San Cecilio University Hospital in Granada in the period July 1, 2020 - December 31, 2020, was performed. All the patients (n = 110) were receiving biological therapy to control the disease. The variables measured included age, sex, time since diagnosis, weight, height, body mass index (BMI), visceral and total fat, and severity parameters. The visceral fat index was evaluated using a bioimpedance scale, considering a cut-off point for a healthy level < 12.


Results: Our sample consisted of 110 patients with a mean age of 47.47 years, with a clear predominance of males (61.7% of patients). After testing for normality using the Kolmogorov-Smirnov test, the Mann-Whitney U test for nonparametric data for independent samples was used, which revealed significant differences between the number of previous treatments and visceral fat (U = -2.235, P = 0.025). No statistically significant differences were found when correlating total fat or visceral fat with BMI.


Conclusions: The results presented lead us to consider if the levels of VAT could be a factor that contributes to some extent to therapeutic refractoriness. The determination of VAT using bioimpedance scales in patients with moderate-severe psoriasis is a valuable method to measure VAT.

Keywords : psoriasis, biological therapy, visceral adipose tissue, treatment, severity

References

1. Vega-Robledo GB, Rico-Rosillo MG. Adipose tissue: Immune function and alterations caused by obesity. Rev Alerg Mex. 2019;66(3):340-353. Spanish. DOI: 10.29262/ram.v66i3.589. PMID: 31606018. 2. Rehrer CW, Karimpour-Fard A, Hernandez TL, et al. Regional differences in subcutaneous adipose tissue gene expression. Obesity (Silver Spring). 2012;20(11):2168-2173. DOI: 10.1038/oby.2012.117. PMID: 22627919; PMCID: PMC3434286.3. Vohl MC, Sladek R, Robitaille J, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004;12(8):1217-1222. DOI: 10.1038/oby.2004.153. PMID: 15340102. 4. Toussirot E, Aubin F, Desmarets M, et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology (Oxford). 2021;60(6):2816-2825. DOI: 10.1093/rheumatology/keaa720. PMID: 33232483.5. Goolam Mahyoodeen N, Crowther NJ, Pillay L, et al. Relationship of visceral fat and adipokines with cardiometabolic diseases in psoriasis. Acta Derm Venereol. 2019; 99:1218–1223. DOI: 10.2340/00015555-3327. PMID: 31580467. 6. Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):e1002739.DOI:10.1371/journal.pmed.1002739. PMID: 30703100; PMCID: PMC6354959. 7. Sajja A, Abdelrahman KM, Reddy AS, et al. Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. JCI Insight. 2020;5(22):e142534. DOI: 10.1172/jci.insight.142534. PMID: 33104056; PMCID: PMC7710282.8. Balci A, Balci DD, Yonden Z, et al. Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome. Dermatology. 2010;220(1):32-37. DOI: 10.1159/000254482. PMID: 19887761. 9. Gönül M, Tatar İ, Canpolat F, Işıl Kurmus G, Ergin C, Hekimoğlu B. Evaluation of abdominal fat index by ultrasonography and its relationship with psoriasis and metabolic syndrome. Postepy Dermatol Alergol. 2017;34(5):453-456. DOI: 10.5114/ada.2017.71111. PMID: 29507560. PMCID: PMC5831280.. 10. Rivers JP, Powell-Wiley TM, Dey AK, et al. Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):349-357. DOI: 10.1016/j.jcmg.2017.08.014. PMID: 29055628. PMCID: PMC5803350.

Send mail to Author


Send Cancel